Paper38832007
Hallmarks of cancer resistance.
Tufail M and 8 others. iScience, 2024. Cited by 93 papers, by iCite.
Cite this record
ConductScience Library. Hallmarks of cancer resistance. Papers, record 38832007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38832007
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References262
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33732706 | Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/33732706 | PubMed |
| 2 | 30429213 | Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy. | Mol Cancer Res | 2019 | https://conductscience.org/library/papers/30429213 | PubMed |
| 3 | 29455658 | Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. | Mol Cancer | 2018 | https://conductscience.org/library/papers/29455658 | PubMed |
| 4 | 37898723 | Immune check points in cancer treatment: current challenges and perspectives. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37898723 | PubMed |
| 5 | 36056935 | IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma. | Immunogenetics | 2023 | https://conductscience.org/library/papers/36056935 | PubMed |
| 6 | 35659296 | Characteristics of the cancer stem cell niche and therapeutic strategies. | Stem Cell Res Ther | 2022 | https://conductscience.org/library/papers/35659296 | PubMed |
| 7 | 37483493 | Editorial: Strategies to overcome tumor evasion and resistance to immunotherapies by targeting immune suppressor cells. | Front Oncol | 2023 | https://conductscience.org/library/papers/37483493 | PubMed |
| 8 | 28274726 | A population genetics perspective on the determinants of intra-tumor heterogeneity. | Biochim Biophys Acta Rev Cancer | 2017 | https://conductscience.org/library/papers/28274726 | PubMed |
| 9 | 35844605 | Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy. | Front Immunol | 2022 | https://conductscience.org/library/papers/35844605 | PubMed |
| 10 | 34484295 | The Role of Mitochondrial DNA Variation in Drug Response: A Systematic Review. | Front Genet | 2021 | https://conductscience.org/library/papers/34484295 | PubMed |
| 11 | 35933332 | Systematic review of circulating MICRORNAS as biomarkers of cervical carcinogenesis. | BMC Cancer | 2022 | https://conductscience.org/library/papers/35933332 | PubMed |
| 12 | 35850748 | Tumor specificity of WNT ligands and receptors reveals universal squamous cell carcinoma oncogenes. | BMC Cancer | 2022 | https://conductscience.org/library/papers/35850748 | PubMed |
| 13 | 32799866 | CircRNAs in anticancer drug resistance: recent advances and future potential. | Mol Cancer | 2020 | https://conductscience.org/library/papers/32799866 | PubMed |
| 14 | 36313628 | The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. | Front Oncol | 2022 | https://conductscience.org/library/papers/36313628 | PubMed |
| 15 | 35505363 | Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells. | Stem Cell Res Ther | 2022 | https://conductscience.org/library/papers/35505363 | PubMed |
| 16 | 31792354 | Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/31792354 | PubMed |
| 17 | 28389777 | Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. | Angiogenesis | 2017 | https://conductscience.org/library/papers/28389777 | PubMed |
| 18 | 33343366 | Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/33343366 | PubMed |
| 19 | 37819576 | Roles of circRNAs in regulating the tumor microenvironment. | Med Oncol | 2023 | https://conductscience.org/library/papers/37819576 | PubMed |
| 20 | 34867402 | Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34867402 | PubMed |
Cited by69
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 93 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42943246 | Ascorbate Enhances the Cytotoxicity of the Manganese-Curcumin-Triphenylphosphonium Complex in Human Cancer Cells. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943246 | PubMed |
| 42936218 | Flavonoids in cancer pharmacology: molecular mechanisms, tumor microenvironment regulation, and drug resistance. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42936218 | PubMed |
| 42924173 | A bibliometric evolution of molecular mechanisms and emerging research trends of therapeutic resistance in oral cancer. | J Dent Sci | 2026 | https://conductscience.org/library/papers/42924173 | PubMed |
| 42769871 | Current Insights into the Role of Peripheral Blood Immune Cell Phenotypes in Resistance to Cancer Therapies. | Oncol Res | 2026 | https://conductscience.org/library/papers/42769871 | PubMed |
| 42640371 | Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines. | Mol Biomed | 2026 | https://conductscience.org/library/papers/42640371 | PubMed |
| 42588713 | Targeting lncRNAs to Overcome Cancer Therapy Resistance: Advances in RNA Therapeutics and Delivery Strategies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588713 | PubMed |
| 42367805 | MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment. | Front Immunol | 2026 | https://conductscience.org/library/papers/42367805 | PubMed |
| 42358772 | pH-Responsive Materials for Therapy and Precision Biomedical Imaging. | Chem Biomed Imaging | 2026 | https://conductscience.org/library/papers/42358772 | PubMed |
| 42357543 | Andean Berry (Vaccinium meridionale Swartz) Juice Promotes Cytotoxic and Proapoptotic Effects in Human Early-Stage and Metastatic Colorectal Cancer Cells. | Molecules | 2026 | https://conductscience.org/library/papers/42357543 | PubMed |
| 42352984 | The Regulatory Network of FOXM1: Orchestrating Cancer Progression and Resistance to Therapy. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42352984 | PubMed |
| 42352266 | The Enigmatic Tumor Suppressor p53 Biomolecule: Its Role and Prognostic and Predictive Values in Cancer Therapy and Precision Medicine. | Biomolecules | 2026 | https://conductscience.org/library/papers/42352266 | PubMed |
| 42233108 | Exploration of miR-326 delivery via biocompatible polymeric nanoparticles in medulloblastoma: A preliminary study. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42233108 | PubMed |
| 42196266 | Machine Learning-Based Identification of Biomarkers for Early-Stage Non-Small Cell Lung Cancer Through Gene Expression Analysis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196266 | PubMed |
| 42193240 | Regulation of Ferroptosis Sensitivity in Hepatocellular Carcinoma Cells by Lysosomal Ion Channels TPC2 and TRPML1. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42193240 | PubMed |
| 42172791 | Translational issues with phototherapy of cancer. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42172791 | PubMed |
| 42146504 | USP1 inhibition promotes RAD18-dependent PCNA degradation and BRCA1 synthetic lethality. | bioRxiv | 2026 | https://conductscience.org/library/papers/42146504 | PubMed |
| 42136309 | 3D-QSAR, Molecular Docking, Molecular Dynamics Simulation, and Pharmacokinetic Prediction of 1H-Pyrazolo[3,4-d]pyrimidine Derivatives as PI3Kδ Inhibitors. | Curr Med Chem | 2026 | https://conductscience.org/library/papers/42136309 | PubMed |
| 42123502 | Anticancer Activity of the Antimicrobial Myristoylated Peptide Myr-B in HeLa Cells: Cytotoxic, Membrane-Disruptive and Proteomic Insights. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42123502 | PubMed |
| 42123327 | Network-Guided Identification of Plant-Derived Modulators of Stress-Adaptive Signalling in Neuroblastoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42123327 | PubMed |
| 42082974 | Transforming tumor microenvironments: nanotechnology and gene therapy in cellular signaling and epigenetic insight into chemo-resistance. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42082974 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38832007
GET https://conductscience.org/api/papers/v1/38832007/references?page=2